Immunotherapy drug avelumab takes on rare penile cancer
NCT ID NCT03391479
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether avelumab, an immunotherapy drug, can shrink tumors in 25 people with advanced penile cancer who cannot take platinum chemotherapy or whose cancer worsened after it. Avelumab works by blocking a protein that helps tumors hide from the immune system. The main goal is to see how many patients respond to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avelumab (an immunotherapy drug that helps the immune system attack cancer cells)
What this could lead to
If it works, this could offer a new treatment option for people with advanced penile cancer who have few alternatives.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects like immune-related inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada